Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS

Yoshino T 1 , Arnold D 2 , Taniguchi H 3 , Pentheroudakis G 4 , Yamazaki K 5 , Xu RH 6 Show all authors , Kim TW 7 , Ismail F 8 , Tan IB 9 , Yeh KH 10 , Grothey A 11 , Zhang S 12 , Ahn JB 13 , Mastura MY 14 , Chong D 9 , Chen LT 15 , Kopetz S 16 , Eguchi-Nakajima T 17 , Ebi H 18 , Ohtsu A 1 , Cervantes A 19 , Muro K 3 , Tabernero J 20 , Minami H 21 , Ciardiello F 22 , Douillard JY 23

Affiliations 

  • 1 Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan
  • 2 CUF Hospitals Cancer Centre, Lisbon, Portugal
  • 3 Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
  • 4 Department of Medical Oncology, University of Ioannina, Ioannina, Greece
  • 5 Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan
  • 6 Department of Medical Oncology, Sun Yat-Sen University (SYSU) Cancer Center, Guangzhou, China
  • 7 Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
  • 8 Department of Radiotherapy & Oncology, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia
  • 9 Division of Medical Oncology, National Cancer Centre, Singapore, Singapore
  • 10 Department of Oncology, National Taiwan University Hospital, and Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan
  • 11 Division of Medical Oncology, Mayo Clinic Cancer Center, Rochester, USA
  • 12 Cancer Institute, Zhejiang University, Hangzhou, China
  • 13 Division of Oncology, Department of Internal Medicine, Yonsei Cancer Center, Seoul, Korea
  • 14 Pantai Cancer Institute, Pantai Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
  • 15 National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan
  • 16 Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Centre, Houston, USA
  • 17 Department of Clinical Oncology, School of Medicine, St. Marianna University, Kanagawa, Japan
  • 18 Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan
  • 19 CIBERONC, Department of Medical Oncology, Institute of Health Research, INCLIVIA, University of Valencia, Valencia, Spain
  • 20 Medical Oncology Department, Vall d' Hebron University Hospital, Vall d'Hebron Institute of Oncology (V.H.I.O.), Barcelona, Spain
  • 21 Department of Medical Oncology and Hematology, Kobe University Hospital, Kobe, Japan
  • 22 Division of Medical Oncology, Seconda Università di Napoli, Naples, Italy
  • 23 ESMO, Viganello-Lugano, Switzerland
Ann Oncol, 2018 01 01;29(1):44-70.
PMID: 29155929 DOI: 10.1093/annonc/mdx738

Abstract

The most recent version of the European Society for Medical Oncology (ESMO) consensus guidelines for the treatment of patients with metastatic colorectal cancer (mCRC) was published in 2016, identifying both a more strategic approach to the administration of the available systemic therapy choices, and a greater emphasis on the use of ablative techniques, including surgery. At the 2016 ESMO Asia Meeting, in December 2016, it was decided by both ESMO and the Japanese Society of Medical Oncology (JSMO) to convene a special guidelines meeting, endorsed by both ESMO and JSMO, immediately after the JSMO 2017 Annual Meeting. The aim was to adapt the ESMO consensus guidelines to take into account the ethnic differences relating to the toxicity as well as other aspects of certain systemic treatments in patients of Asian ethnicity. These guidelines represent the consensus opinions reached by experts in the treatment of patients with mCRC identified by the Presidents of the oncological societies of Japan (JSMO), China (Chinese Society of Clinical Oncology), Korea (Korean Association for Clinical Oncology), Malaysia (Malaysian Oncological Society), Singapore (Singapore Society of Oncology) and Taiwan (Taiwan Oncology Society). The voting was based on scientific evidence and was independent of both the current treatment practices and the drug availability and reimbursement situations in the individual participating Asian countries.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications